The FDA announced that the shortage of tirzepatide injection has been resolved, with Lilly able to meet national demand. Compounders are prohibited from making the product, but supply chain issues may still cause disruptions for patients and prescribers. The Alliance for Pharmacy Compounding alerted members to stop making compounded copies of the drug, which could lead to patient access issues. Endocrinologists express cautious optimism about the resolution, despite concerns about potential confusion and access barriers for patients. The impact of the shortage on endocrinologists and obesity medicine specialists has been previously reported, highlighting concerns about compounding pharmacies.
Source link
Tirzepatide Shortage Resolved? FDA Says Yes, Compounders No
